Anxiety, Depression, Suicidal Ideation
Conditions
Brief summary
This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among adults. The first 450 participants will participate in a randomized waitlist controlled trial. The remaining 550 participants will be provided the program immediately upon enrolling
Detailed description
The efficacy of Thrive has been studied among patient and community populations and has shown to effectively reduce depression and anxiety symptoms among adults with moderate to severe depression symptoms at baseline. This study will examine whether Thrive can also reduce suicidal thinking for persons exhibiting at least moderate depression symptoms. The first phase of the study will implement a randomized waitlist controlled trial. The second phase of the study will examine the effects in a open trial. Outcome assessments will occur at baseline, 4- and 8-weeks (12- and 16-weeks for the waitlist group) with a 6-month follow-up assessment for all participants.
Interventions
BEHAVIORALThrive
Computerized Cognitive Behavior Therapy program
Sponsors
Montana Department of Public Health and Human Services
Montana State University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
randomized waitlist controlled trial (first ?? participants) Open trial (following ?? participants)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Montana resident * 18+ years old * Have regular access to broadband internet * PHQ-9 score greater than 4
Exclusion criteria
* No Montana residency * \< 18 years old * No broadband internet access * PHQ-9 score less than 5
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concise Health Risk Tracking | 2 Weeks | Suicidal Thinking; Score range 7 (better) - 35(worse) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Generalized Anxiety Disorder Scale-7 | 2 Weeks | Anxiety symptoms; Score range 0 (better) to 21 (worse) |
| Work and Social Adjustment Scale | 1 Year | Functioning; Score range 0(better) - 40(worse) |
| Connor-Davidson Resilience Scale - Abbreviated Version | 1 month | Resilience; score range 0 (worse) - 40(better) |
| Patient Health Questionnaire-9 | 2 Weeks | Depression; Score range 0(better) - 27(worse) |
Countries
United States
Outcome results
None listed